# SYNTHESIS OF UP TO TEN SAMPLE COMPOUNDS PER YEAR (Option Yr 1)

> **NIH NIH N02** · ALCHEM LABORATORIES CORPORATION · 2022 · $637,251

## Abstract

The Developmental Therapeutics Program/DCTD utilizes the Drug Acquisition Initiative (DAI) to independently acquire gram quantities of all known therapeutic agents that are under human clinical development for the treatment of cancer.  As part of the DAI the Drug Synthesis and Chemistry Branch periodically engages its contractors to synthesize gram quantities of select compounds.  The Synthesis Target 1 Project is directed at the synthesis of a minimum of 5 grams of 1-(4-(benzylamino)-5,6,7,8-tetrahydropyrido[2,3-d]pyrimidin-2-yl)-2-methyl-1H-indole-4-carboxamide, designated as CB-5339 and NSC831868.

## Key facts

- **NIH application ID:** 10701635
- **Project number:** 261201700007I-P00001-759102100001-1
- **Recipient organization:** ALCHEM LABORATORIES CORPORATION
- **Principal Investigator:** JAMES TALTON
- **Activity code:** N02 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $637,251
- **Award type:** —
- **Project period:** 2021-09-20 → 2023-09-19

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10701635

## Citation

> US National Institutes of Health, RePORTER application 10701635, SYNTHESIS OF UP TO TEN SAMPLE COMPOUNDS PER YEAR (Option Yr 1) (261201700007I-P00001-759102100001-1). Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/grant/nih/10701635. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*